5α-reductase type 3 enzyme in benign and malignant prostate

Department of Urology, Roswell Park Cancer Institute, Buffalo, New York.
The Prostate (Impact Factor: 3.57). 02/2014; 74(3). DOI: 10.1002/pros.22745
Source: PubMed


Currently available 5α-reductase inhibitors are not completely effective for treatment of benign prostate enlargement, prevention of prostate cancer (CaP), or treatment of advanced castration-recurrent (CR) CaP. We tested the hypothesis that a novel 5α-reductase, 5α-reductase-3, contributes to residual androgen metabolism, especially in CR-CaP.
A new protein with potential 5α-reducing activity was expressed in CHO-K1 cellsandTOP10 E. coli for characterization. Protein lysates and total mRNA were isolated from preclinical and clinical tissues. Androgen metabolism was assessed using androgen precursors and thin layer chromatography or liquid chromatography tandem mass spectrometry.
The relative mRNA expression for the three 5α-reductase enzymes in clinical samples of CR-CaP was 5α-reductase-3 ≫ 5α-reductase-1 > 5α-reductase-2. Recombinant 5α-reductase-3 protein incubations converted testosterone, 4-androstene-3,17-dione (androstenedione) and 4-pregnene-3,20-dione (progesterone) to dihydrotestosterone, 5α-androstan-3,17-dione, and 5α-pregnan-3,20-dione, respectively. 5α-Reduced androgen metabolites were measurable in lysates from androgen-stimulated (AS) CWR22 and CR-CWR22 tumors and clinical specimens of AS-CaP and CR-CaP pre-incubated with dutasteride (a bi-specific inhibitor of 5α-reductase-1 and 2).
Human prostate tissues contain a third 5α-reductase that was inhibited poorly by dutasteride at high androgen substrate concentration in vitro, and it may promote DHT formation in vivo, through alternative androgen metabolism pathways when testosterone levels are low. Prostate © 2013 Wiley Periodicals, Inc.

Download full-text


Available from: Mark Titus, Feb 21, 2014
31 Reads
  • Source
    • "Although this hypothesis has not been investigated in humans, it should be tested in the future. In addition, 5a-reductase type 3 was recently shown to be expressed in benign and malignant prostate [23] [30], and overexpressed in CRPC tissues [31]. Therefore, a 5a-reductase inhibitor targeting all isoforms might be a more powerful modality combined with castration, and this hypothesis should be examined in preclinical studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: De novo androgen synthesis is thought to be involved in the progression to castration-resistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT). During androgen synthesis, 5α-reductase encoded by SRD5A catalyses testosterone into more active dihydrotestosterone and may be involved in the progression to CRPC. Then, this study aimed to reveal the association between genetic variations in SRD5A and the prognosis in metastatic prostate cancer. We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT. The association between the polymorphisms and the progression to CRPC as well as overall survival was examined. Patients carrying the more active GG genotype in SRD5A2 rs523349 exhibited a higher risk of the progression (hazard ration [95% confidence interval], 1.93 [1.14-3.14], p=0.016) and death (hazard ration [95% confidence interval], 2.14 [1.16-3.76], p=0.016), compared with less active GC/CC genotypes in SRD5A2 rs523349. High 5α-reductase activity due to the polymorphism in SRD5A2 may contribute to resistance to ADT. Furthermore, SRD5A2 rs523349 polymorphism may be a promising biomarker for metastatic prostate cancer patients treated with primary ADT and a molecular target for advanced prostate cancer. Copyright © 2015 Elsevier Ltd. All rights reserved.
    European journal of cancer (Oxford, England: 1990) 07/2015; 51(14). DOI:10.1016/j.ejca.2015.06.122 · 5.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Underage drinking is a leading public health problem in developed countries. An increasing proportion of adolescents consume alcoholic beverages every weekend. Increased anxiety, irritability, and depression among adolescents may induce them to seek for the anxiolytic and rewarding properties of alcohol. Allopregnanolone (AlloP) shares rewarding effects of ethanol and modulates ethanol intake. The rate-limiting enzyme in the biosynthesis of AlloP is steroid 5α-reductase (5α-R), which is expressed as three isozymes, 5α-R1, 5α-R2, and 5α-R3. The objective of this study was to quantify the expression levels of 5α-R isozymes in prefrontal cortex (PFC) of adolescent male rats after three different regimes of ethanol administration. Adolescent male Wistar rats were administered with ethanol (4 g/kg) or saline intraperitoneally for 1 day (acute), for 7 days (chronic), or every 72 h for 14 days (chronic intermittent). Messenger (m)RNA and protein levels of 5α-R isozymes were measured by quantitative RT-PCR and Western blot, respectively. Ethanol significantly increased mRNA and protein levels of 5α-R1, 5α-R2, and 5α-R3 in the three different regimes of ethanol administration, being higher in the chronic intermittent regime in comparison with the others. The expression of the AlloP-biosynthetic enzyme 5α-Rs increases in the prefrontal cortex of adolescent male rats under acute, chronic, and chronic intermittent regime of ethanol administration. The latter is very interesting because it mimics the teenage drinking behavior.
    Psychopharmacology 04/2014; 231(17). DOI:10.1007/s00213-014-3558-6 · 3.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the second leading cause of cancer death in adult males in the United States. Recent advances have found that the fatal form of this cancer known as castration resistant prostate cancer (CRPC) remains hormonally driven despite castrate levels of circulating androgens. CRPC arises since the tumor undergoes adaptation to low levels of androgens by either synthesizing its own androgens (intratumoral androgens) or by alterations in the androgen receptor (AR). This article reviews the major routes to testosterone and dihydrotestosterone in CRPC, examines the enzyme targets and progress in the development of isoform specific inhibitors that could block intratumoral androgen biosynthesis. Because redundancy exists in these pathways it is likely that inhibition of a single pathway will lead to up-regulation of another so that drug resistance would be anticipated. Drugs that target multiple pathways or agents that block intratumoral androgen biosynthesis and antagonize the AR offer the most promise. Optimal use of enzyme inhibitors or AR antagonists to ensure maximal benefit to CRPC patients will also require application of precision molecular medicine to determine that a tumor in a particular patient will be responsive to these treatments either alone or in combination.
    Endocrine Related Cancer 05/2014; 21(4). DOI:10.1530/ERC-14-0109 · 4.81 Impact Factor
Show more